From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Collagenase, Type VIII is a mixed enzyme derived from Clostridium histolyticum that contains collagenase, a nonspecific protease, and a clostripain. Collagenase, Type VIII can hydrolyze Type VIII collagen and may be used to study the formation of atherosclerosis. Type VIII collagen is a regulator of endothelialcell differentiation and angiogenesis, a substrate for celladhesion and migration such as smooth muscle cells, and may accumulate in atherosclerosis. After endotoxin activates the expression of Collagenase, Type VIII, it can reduce the production of Type VIII collagen and has the potential to inhibit atherosclerosis .
Gypenoside XLIX is a multifunctional bioactive compound that can be isolated from Gynostemma pentaphyllum, with a Ka value of 1.58 μM for its binding to SIRT1. Gypenoside XLIX acts as a PPAR-α agonist. It inhibits the activation of TLR4-mediated NF-κB signaling pathway by activating the Sirt1/Nrf2 signaling pathway, reduces ROS accumulation, and alleviates hepatic inflammatory injury in mice with sepsis-induced liver disease. Gypenoside XLIX targets SIRT1 to block YAP-NLRP3 activation and improve sepsis-induced cardiomyopathy. Gypenoside XLIX inhibits apoptosis (Apoptosis), pyroptosis (Pyroptosis), autophagy (Autophagy), lipid peroxidation, pro-inflammatory cytokines and anti-inflammatory cytokines. Gypenoside XLIX alleviates sepsis-induced splenic injury by inhibiting inflammation and oxidative stress, and mitigates sepsis-associated encephalopathy by targeting PPAR-α. Gypenoside XLIX prevents acute kidney injury by inhibiting IGFBP7/IGF1R-mediated programmed cell death and inflammation. Gypenoside XLIX inhibits the expression and activity of vascular celladhesion molecule-1 in cytokine-induced human endothelialcells. Gypenoside XLIX is applicable to research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis and chronic inflammation .
Surfactin C1 is an amphiphilic biosurfactants. Surfactin C1 inhibits leukemic cell (HL-60) adhesion to human umbilical vein endothelialcells (HUVEC). Surfactin C1 inhibits adhesion melecules expression, such as ICAM-1 and VCAM-1 .
Obtustatin is a non-RGD disintegrin consisting of 41 residues. Obtustatin inhibits the adhesion of α1β1 integrin to type IV Collagen (HY-NP003), blocks α1β1 integrin signaling in endothelialcells, and suppresses FGF2-induced angiogenesis. Obtustatin inhibits tumor progression in mouse models and upregulates VEGF expression in sarcoma-bearing mice. Obtustatin can be used in research related to Lewis lung carcinoma and S-180 sarcoma .
Rhamnocitrin is an anti-inflammatory and antioxidant agent that targets STIM-1, NFATc3 and MAPK pathways and can scavenge DPPH (IC50=28.38 mM). Rhamnocitrin selectively inhibits oxidative stress and inflammatory responses in vascular endothelialcells and neurons. Rhamnocitrin up-regulates miR-185 to inhibit STIM-1-mediated store-operated calcium entry (SOCE), thereby blocking NFATc3 nuclear translocation and downstream inflammatory factor expression, while inducing heme oxygenase HO-1 expression and regulating the ERK/p38 MAPK pathway, inhibiting antioxidant and pro-inflammatory cytokines (such as IL-6, IL-8) and adhesion molecules (such as ICAM-1, VCAM-1). Rhamnocitrin can be used in the study of endothelial-related inflammatory diseases (such as sepsis, acute lung injury, atherosclerosis) and neuroprotection (such as oxidative damage of PC12 cells) .
REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV can be used for the research of cell adhesion. REDV is used to study the effects of gene vectors containing REDV on cells .
Intetumumab (CNTO 95) is a human monoclonal antibody targeting αv integrin, with a Kd value of 1-24 nM. Through high-affinity binding to αv integrin, Intetumumab inhibits its interaction with extracellular matrix proteins (such as vitronectin and fibronectin), thereby blocking the downstream focal adhesion kinase signaling pathway. This further inhibits the adhesion, migration and invasion of tumor cells as well as the proliferation of vascular endothelialcells, promotes cellapoptosis, and exerts anti-tumor and anti-angiogenic effects. Intetumumab can be used in research related to head and neck cancer, non-small cell lung cancer and uterine serous papillary carcinoma .
E (c (RGDfK)) 2 is a αvβ3 integrin ligand and tumor-targeting agent. E (c (RGDfK)) 2 binds to αvβ3 integrin, mediates receptor-mediated endocytosis of conjugated payloads, and inhibits integrin-dependent celladhesion to fibrinogen. E (c (RGDfK)) 2 inhibits the proliferation of cancer cells and endothelialcells. E (c (RGDfK)) 2 preferentially accumulates in orthotopic mouse breast tumors and human ovarian cancer xenograft tumors. E (c (RGDfK)) 2 can be used in research related to glioblastoma, lung cancer, breast adenocarcinoma and ovarian cancer .
Etaracizumab (LM 609) is an αvβ3 integrin IgG mAb. Etaracizumab is developed to target αvβ3+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofαvβ3-mediated celladhesion, endothelialcell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
GSK1995057 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK1995057 selectively binds to TNFR1, blocks the binding of TNF-α and LT-α, and does not interfere with TNFR2 signaling. GSK1995057 inhibits the activation of NF-κB, JNK and MAPK pathways, alleviates apoptosis (apoptosis) and inflammatory responses (inhibiting IL-1β, IL-6, IL-10, TNF-α), and prevents viability loss of human nucleus pulposus cells. GSK1995057 inhibits the expression of cytokines and neutrophil adhesion molecules in human pulmonary microvascular endothelialcell monolayers, and reduces inflammatory responses and lung injury symptoms in non-human primates. GSK1995057 forms complexes with HAVH autoantibodies, thereby activating TNFR1 and triggering the release of cytokines and IL-8 in human cells. GSK1995057 can be used in research related to intervertebral disc degeneration and acute lung injury .
β-Estradiol 17-acetate (1,3,5(10)-Estratriene-3,17β-diol 17-acetate) is a long-acting endogenous estrogen precursor and also a cell viability and proliferation enhancer. β-Estradiol 17-acetate promotes the adhesion and proliferation of freshly isolated and revived female-derived human brain microvascular endothelialcells, and reverses the decreased viability of revived male-derived human brain microvascular endothelialcells. β-Estradiol 17-acetate exerts the microvascular protective effect of estrogen, enabling non-tumor human brain microvascular endothelialcells to be cultured in vitro for 2 months after cryopreservation. β-Estradiol 17-acetate is biotransformed into β-estradiol via hydrolase action in the in vitro skin of humans, hairless dogs, rats and hairless mice .
Vasculotide is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelialcell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability . Vasculotide alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide with antibiotics reduces lung injury .
Rivipansel is a small-molecule glycomimetic pan-selectin antagonist with inhibitory activity against E-selectin and P-selectin. Rivipansel binds tightly to the lectin domain of E-selectin, and selectively blocks the recognition of CD62L by E-selectin without affecting the binding of PSGL-1 to E-selectin. Rivipansel functionally inhibits the adhesion of hematopoietic cells to endothelialcells, and is applicable to research related to sickle cell disease .
SB-657510 is a selective urotensin II (UII) receptor (UT) antagonist. The Ki values are 61, 17, 30, 65 and 56 nM for human, monkey, cat, rat and mouse receptors, respectively. SB-657510 exerts anti-inflammatory effects by inhibiting UII-induced upregulation of inflammatory mediators such as adhesion molecules, cytokines, and tissue factor in human vascular endothelialcells .
Macrophage-activating lipopeptide 2 TFA is an agonist of Toll like receptors TLR-2/TLR-6. Macrophage-activating lipopeptide-2 enhances endothelial nitric oxide synthase (eNOS) phosphorylation and endothelialcell release of NO, thereby improving vasodilation. Macrophage-activating lipopeptide-2 enhances endothelialadhesion of white blood cells and improve perfusion recovery and collateral growth in the hind limbs of hypercholesterolemic Apoe deficient mice undergoing experimental femoral artery ligation (FAL) .
CXCL8 (54-72) is a C-terminal peptide based on the chemokine CXCL8. CXCL8 (54-72) has an interaction between a long and highly positively charged C-terminal region and a negative charge on the GAG that binds to the GAG. CXCL8 (54-72) can inhibit the adhesion and migration of neutrophils and adhesion of endothelialcells. CXCL8 (54-72) can be used to study chemokines in inflammatory response .
Vasculotide TFA is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide TFA binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelialcell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability . Vasculotide TFA alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide TFA with antibiotics reduces lung injury .
T7 Peptide is a protein synthesis inhibitor and anti-angiogenic agent, with a Kd of 10 nM for human transferrin receptor. T7 Peptide inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of 4E-BP1 in endothelialcells. T7 Peptide induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma .
T7 Peptide TFA is a protein synthesis inhibitor and anti-angiogenic agent, with a Kd of 10 nM for human transferrin receptor. T7 Peptide TFA inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of 4E-BP1 in endothelialcells. T7 Peptide TFA induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide TFA is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma .
Anti-Mouse CD31/PECAM-1 Antibody (390) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse CD31/PECAM-1. Anti-Mouse CD31/PECAM-1 Antibody (390) reacts with mouse CD31, also known as PECAM-1 (platelet endothelialcelladhesion molecule). Anti-Mouse CD31/PECAM-1 Antibody (390) inhibits angiogenesis. Anti-Mouse CD31/PECAM-1 Antibody (390) can be used for the research of cancer, such as A549 tumor .
Aureothricin is a dithiolopyrrolone (DTP) antibiotic first isolated from Streptomyces and exhibits relatively broad-spectrum antibiotic activity. Aureothricin can inhibit adhesion of human umbilical vein endothelialcells (HUVECs) to vitronectin .
DSPE-PEG2000-YIGSR is a PEG compound which composed of DSPE and a biomimetic peptide YIGSR. YIGSR interacts with the 67 kDa laminin binding protein (LBP) and promotes adhesion and spreading of a large number of cell types including endothelialcells, fibroblasts and smooth muscle cells. DSPE-PEG2000-YIGSR can be used for drug delivery .
Macrophage-activating lipopeptide 2 (MALP-2) is an agonist of Toll like receptors TLR-2/TLR-6. Macrophage-activating lipopeptide-2 can enhance endothelial nitric oxide synthase (eNOS) phosphorylation and endothelialcell release of NO, thereby improving vasodilation. Macrophage-activating lipopeptide-2 can enhance endothelialadhesion of white blood cells and improve perfusion recovery and collateral growth in the hind limbs of hypercholesterolemic Apoe deficient mice undergoing experimental femoral artery ligation (FAL) .
ZD 2138 is a selective 5-lipoxygenase (5-lipoxygenase) inhibitor with an IC50 of 20-50 nM. ZD 2138 inhibits cytokine-induced rolling and adhesion of leukocytes on bovine aortic endothelialcells. ZD 2138 is applicable to research related to inflammatory diseases such as acute asthma .
CD31 (PECAM-1) is platelet endothelialcelladhesion molecule-1, serves as the endothelialcell-specific receptor of clostridium perfringens b-Toxin (CPB). CD31 is also an ER-MP12 antigen, acts as a linker between mechanical stress, metabolism and inflammation. CD31 peptide is able to sustain phosphorylation of the CD31 ITIM686 and of SHP2 and to inhibit TCR-induced T-cell activation - .
Anti-Mouse ICOSL/CD275 Antibody (HK5.3) is an anti-mouse ICOSL/CD275 IgG2a monoclonal antibody. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can inhibit the adhesion between T cells and endothelialcells. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can reduce the expansion of tissue resident (TR) Treg cells. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can be used for researches on inflammation and infection conditions such as influenza virus infection and arthritis .
SSAO/VAP-1 inhibitor 1 is a potent inhibitor of SSAO/VAP-1. SSAO/VAP-1 promotes the transfer of Glucose transport 4 (GLUT 4) from adipocytes to the cell membrane, thereby regulating glucose transport. In endothelialcells, SSAO/VAP-1 can mediate the adhesion and exudation of leukocytes and endothelialcells, and participate in inflammatory responses. SSAO/VAP-1 inhibitor 1 has the potential for the research of inflammation and/or inflammation-related disease or diabetes and/or diabetes-related disease (extracted from patent WO2021102774A1, compound E3) .
YF-452 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2). YF-452 remarkably inhibits the migration, invasion and tube-like structure formation of human umbilical vein endothelialcells (HUVECs) with little toxicity. YF-452 inhibits VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal regulated kinase (ERK), focal adhesion kinase (FAK) and Src. YF-452 is a potential antiangiogenic agent candidate for cancer research .
Cariporide is a Na+/H+ Exchanger 1 (NHE-1) inhibitor. Cariporide inhibits the expression of monocyte endothelialcelladhesion and intercellular adhesion molecule-1 (ICAM-1) mediated by high glucose (HG) by inhibiting the activation of NHE-1 .
Cadherin Peptide, avian is a calcium-dependent glycoprotein. Cadherin Peptide, avian takes part in homophilic cell-celladhesion and dose-dependently inhibits bovine brain microvessel endothelialcells (BBMECs) adhesion .
Human PECAM1 mRNA encodes the human platelet and endothelialcelladhesion molecule 1 (PECAM1) protein, a member of the immunoglobulin superfamily. PECAM1 is likely involved in leukocyte migration, angiogenesis, and integrin activation.
CD31 (PECAM-1) TFA is platelet endothelialcelladhesion molecule-1, serves as the endothelialcell-specific receptor of clostridium perfringens b-Toxin (CPB). CD31 TFA is also an ER-MP12 antigen, acts as a linker between mechanical stress, metabolism and inflammation. CD31 TFA peptide is able to sustain phosphorylation of the CD31 ITIM686 and of SHP2 and to inhibit TCR-induced T-cell activation - .
Anti-E-Selectin Antibody (CL2) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human E-Selectin. Anti-E-Selectin Antibody (CL2) reacts with human E-selectin also known as CD62E, endothelial-leukocyte adhesion molecule 1 (ELAM-1), and leukocyte-endothelialcelladhesion molecule 2 (LECAM2). Anti-E-Selectin Antibody (CL2) directly blocks the binding of E selectin to carbohydrate ligands. Anti-E-Selectin Antibody (CL2) can be used for the detection of flow cytometry .
N-Octanoyl dopamine is superior to dopamine in protecting graft contractile function when administered to the heart transplant recipients from brain-dead donors. N-Octanoyl dopamine inhibits cytokine production in activated T-cells and diminishes MHC-class-II expression as well as adhesion molecules in IFNγ-stimulated endothelialcells .
DSPE-PEG1000-YIGSR is a PEG compound which composed of DSPE and a biomimetic peptide YIGSR. YIGSR interacts with the 67 kDa laminin binding protein (LBP) and promotes adhesion and spreading of a large number of cell types including endothelialcells, fibroblasts and smooth muscle cells. DSPE-PEG1000-YIGSR can be used for drug delivery .
DSPE-PEG3400-YIGSR is a PEG compound which composed of DSPE and a biomimetic peptide YIGSR. YIGSR interacts with the 67 kDa laminin binding protein (LBP) and promotes adhesion and spreading of a large number of cell types including endothelialcells, fibroblasts and smooth muscle cells. DSPE-PEG3400-YIGSR can be used for drug delivery .
Gypenoside XLIX (Standard) is the analytical standard of Gypenoside XLIX. This product is intended for research and analytical applications. Gypenoside XLIX, a dammarane-type glycoside, is a prominent component of G. pentaphyllum. Gypenoside XLIX is a selective peroxisome proliferator-activated receptor (PPAR)-alpha activator and inhibits cytokine-induced vascular celladhesion molecule-1 (VCAM-1) overexpression and hyperactivity in human endothelialcells .
Gypenoside XLIX (Standard) is the analytical standard of Gypenoside XLIX. This product is intended for research and analytical applications. Gypenoside XLIX, a dammarane-type glycoside, is a prominent component of G. pentaphyllum. Gypenoside XLIX is a selective peroxisome proliferator-activated receptor (PPAR)-alpha activator and inhibits cytokine-induced vascular celladhesion molecule-1 (VCAM-1) overexpression and hyperactivity in human endothelialcells .
15-Deoxy-Δ12,14-prostaglandin A1 is a deoxyanalog of prostaglandins that inhibits NF-κB signaling and induces apoptosis. 15-Deoxy-Δ12,14-prostaglandin A1 inhibits TNF-α-induced upregulation of inflammatory endothelialcelladhesion molecule (CAM) and avoids monocyte arrest .
17-Epiestriol is an estrogen metabolite and a selective estrogen receptor (ER) β agonist. 17-epiestriol inhibits the mRNA and protein expression of the vascular celladhesion molecule VCAM-1 induced by tumor necrosis factor α (TNFα). 17-epiestriol also inhibits TNFα-induced VCAM-1 expression and prevents NF-κB migration to the nucleus. 17-Epiestriol also induces the mRNA and protein expression of endothelial nitric oxide synthase .
Rhamnocitrin (Standard) is the analytical standard of Rhamnocitrin. This product is intended for research and analytical applications. Rhamnocitrin is an anti-inflammatory and antioxidant agent that targets STIM-1, NFATc3 and MAPK pathways and can scavenge DPPH (IC50=28.38 mM). Rhamnocitrin selectively inhibits oxidative stress and inflammatory responses in vascular endothelialcells and neurons. Rhamnocitrin up-regulates miR-185 to inhibit STIM-1-mediated store-operated calcium entry (SOCE), thereby blocking NFATc3 nuclear translocation and downstream inflammatory factor expression, while inducing heme oxygenase HO-1 expression and regulating the ERK/p38 MAPK pathway, inhibiting antioxidant and pro-inflammatory cytokines (such as IL-6, IL-8) and adhesion molecules (such as ICAM-1, VCAM-1). Rhamnocitrin can be used in the study of endothelial-related inflammatory diseases (such as sepsis, acute lung injury, atherosclerosis) and neuroprotection (such as oxidative damage of PC12 cells) .
17-Epiestriol-d5-1 is the deuterium labeled 17-Epiestriol (HY-163712). 17-Epiestriol is an estrogen metabolite and a selective estrogen receptor (ER) β agonist. 17-epiestriol inhibits the mRNA and protein expression of the vascular celladhesion molecule VCAM-1 induced by tumor necrosis factor α (TNFα). 17-epiestriol also inhibits TNFα-induced VCAM-1 expression and prevents NF-κB migration to the nucleus. 17-Epiestriol also induces the mRNA and protein expression of endothelial nitric oxide synthase .
REDV TFA is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV TFA can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV TFA can be used for the research of cell adhesion .
DSPE-PEG5000-YIGSR is a PEG compound which composed of DSPE and a biomimetic peptide YIGSR. YIGSR interacts with the 67 kDa laminin binding protein (LBP) and promotes adhesion and spreading of a large number of cell types including endothelialcells, fibroblasts and smooth muscle cells. DSPE-PEG5000-YIGSR can be used for drug delivery .
SVVYGLR is an osteopontin-derived peptide. SVVYGLR can promote the differentiation of fibroblasts into myofibroblast-like cells and promote the production of type III collagen by cardiac fibroblasts. SVVYGLR can activate the adhesion, migration and tubule formation of endothelialcells in vitro. SVVYGLR promotes angiogenesis and wound healing and promotes the migration of dermal fibroblasts and keratinocytes. SVVYGLR can be used for research related to angiogenesis, dermal wounds and bone regeneration .
AT1412 is a CD9-binding antibody. AT1412 binds to the tetraspanin protein CD9 and modulates CD9 function by enhancing T celladhesion to endothelialcells (HUVECs) and transendothelial migration. AT1412 binds to B-ALL cell lines but not to T-ALL. AT1412 induces antibody-dependent cellular cytotoxicity in B-ALL cell lines. AT1412 binds to melanoma cells, B-ALL, gastric cancer, colorectal cancer, and pancreatic cancer cells [1] .
IPS-05002 is an α5β1 antagonist. IPS-05002 can inhibit VEGF-stimulated human umbilical vein endothelialcell (HUVEC) proliferation, adhesion, and migration, and also suppresses tubular network formation. IPS-05002 can upregulate IKB-β, XRCC4, and downregulate Cdc6 in VEGF-induced HUVECs. IPS-05002 can be used for the study of tumor angiogenesis .
Peptide E5 is an antagonist targeting the CXCR4/CXCL12 axis. Peptide E5 blocks the CXCR4/CXCL12 axis, downregulates CXCR4 expression, and inhibits the phosphorylation of downstream Akt and Erk. Peptide E5 induces apoptosis, suppresses migration and adhesion of breast cancer cells. Peptide E5 inhibits CXCL12-mediated endothelial progenitor cell recruitment, thereby suppressing tumor angiogenesis. Peptide E5 is applicable to relevant research on breast cancer .
SB-657510 (Standard) is the analytical standard of SB-657510 (HY-10656). This product is intended for research and analytical applications. SB-657510 is a selective urotensin II (UII) receptor (UT) antagonist. The Ki values are 61, 17, 30, 65 and 56 nM for human, monkey, cat, rat and mouse receptors, respectively. SB-657510 exerts anti-inflammatory effects by inhibiting UII-induced upregulation of inflammatory mediators such as adhesion molecules, cytokines, and tissue factor in human vascular endothelialcells .
AM9928 is a monoacylglycerol lipase (MAGL) inhibitor with IC50 and Ki values of 8.9 nM and 7.3 nM, respectively. AM9928 blocks the adhesion and migration of triple-negative breast cancer (TNBC) cells, and inhibits the secretion of IL-6, IL-8 and VEGF-A by TNBC cells. AM9928 suppresses the activation of human brain microvascular endothelialcells (HBMECs) induced by TNBC-derived exosomes, and reduces the secretion of IL-8 and VEGF-A by HBMECs. AM9928 attenuates changes in blood-brain barrier permeability, inhibits tumor growth in the mammary fat pad, and reduces brain colonization of TNBC. AM9928 can be used in studies related to triple-negative breast cancer .
NVP-TAC544 is a focal adhesion kinase (FAK) inhibitor. NVP-TAC544 inhibits angiogenesis. NVP-TAC544 can be used for the research of melanoma (primary or metastatic) .
Resolvin D5 n-3 DPA is a Docosapentaenoic acid (DPA) derived specialized proresolving lipid mediator (SPM). Resolvin D5 n-3 DPA is a GPR101, GPR12, and GPR84 agonist with EC50s of 4.6 pM, 14 pM, and 1.5 pM, respectively. Resolvin D5 n-3 DPA possesses potent pro-resolution and anti-inflammatory actions. Resolvin D5 n-3 DPA reduces celladhesion onto TNF-α-activated human endothelial monolayers. Resolvin D5 n-3 DPA displays potent leukocyte-directed activities, upregulating the ability of neutrophils and macrophages to phagocytose bacteria. Resolvin D5 n-3 DPA can be used for the study of intestinal inflammation .
DSPE-PEG2000-YIGSR is a PEG compound which composed of DSPE and a biomimetic peptide YIGSR. YIGSR interacts with the 67 kDa laminin binding protein (LBP) and promotes adhesion and spreading of a large number of cell types including endothelialcells, fibroblasts and smooth muscle cells. DSPE-PEG2000-YIGSR can be used for drug delivery .
DSPE-PEG1000-YIGSR is a PEG compound which composed of DSPE and a biomimetic peptide YIGSR. YIGSR interacts with the 67 kDa laminin binding protein (LBP) and promotes adhesion and spreading of a large number of cell types including endothelialcells, fibroblasts and smooth muscle cells. DSPE-PEG1000-YIGSR can be used for drug delivery .
DSPE-PEG3400-YIGSR is a PEG compound which composed of DSPE and a biomimetic peptide YIGSR. YIGSR interacts with the 67 kDa laminin binding protein (LBP) and promotes adhesion and spreading of a large number of cell types including endothelialcells, fibroblasts and smooth muscle cells. DSPE-PEG3400-YIGSR can be used for drug delivery .
DSPE-PEG5000-YIGSR is a PEG compound which composed of DSPE and a biomimetic peptide YIGSR. YIGSR interacts with the 67 kDa laminin binding protein (LBP) and promotes adhesion and spreading of a large number of cell types including endothelialcells, fibroblasts and smooth muscle cells. DSPE-PEG5000-YIGSR can be used for drug delivery .
Surfactin C1 is an amphiphilic biosurfactants. Surfactin C1 inhibits leukemic cell (HL-60) adhesion to human umbilical vein endothelialcells (HUVEC). Surfactin C1 inhibits adhesion melecules expression, such as ICAM-1 and VCAM-1 .
Laminin peptide CDPGYIGSR (Laminin (925-933)) TFA is a 67 kDa laminin receptor ligand and selective celladhesion inducer. Laminin peptide CDPGYIGSR TFA not only promotes celladhesion and mediates directed neurite outgrowth via matrix coating or covalent immobilization, but also inhibits neural crest cell migration under specific conditions. Laminin peptide CDPGYIGSR TFA inhibits lung colonization of melanoma cells, and suppresses the growth of Sarcoma 180 solid tumors and Lewis lung carcinoma (3LL) in mice. Laminin peptide CDPGYIGSR TFA also exerts significant anti-angiogenic effects by inhibiting embryonic angiogenesis in the chick chorioallantoic membrane and vascular endothelialcell migration induced by tumor-conditioned medium. Laminin peptide CDPGYIGSR TFA can be widely used in studies related to melanoma, Sarcoma 180, Lewis lung carcinoma (3LL), and other relevant areas .
Obtustatin is a non-RGD disintegrin consisting of 41 residues. Obtustatin inhibits the adhesion of α1β1 integrin to type IV Collagen (HY-NP003), blocks α1β1 integrin signaling in endothelialcells, and suppresses FGF2-induced angiogenesis. Obtustatin inhibits tumor progression in mouse models and upregulates VEGF expression in sarcoma-bearing mice. Obtustatin can be used in research related to Lewis lung carcinoma and S-180 sarcoma .
REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV can be used for the research of cell adhesion. REDV is used to study the effects of gene vectors containing REDV on cells .
E (c (RGDfK)) 2 is a αvβ3 integrin ligand and tumor-targeting agent. E (c (RGDfK)) 2 binds to αvβ3 integrin, mediates receptor-mediated endocytosis of conjugated payloads, and inhibits integrin-dependent celladhesion to fibrinogen. E (c (RGDfK)) 2 inhibits the proliferation of cancer cells and endothelialcells. E (c (RGDfK)) 2 preferentially accumulates in orthotopic mouse breast tumors and human ovarian cancer xenograft tumors. E (c (RGDfK)) 2 can be used in research related to glioblastoma, lung cancer, breast adenocarcinoma and ovarian cancer .
Vasculotide is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelialcell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability . Vasculotide alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide with antibiotics reduces lung injury .
Fibronectin Adhesion-promoting Peptide (Heparin Binding Peptide) is one of the heparin-binding amino acid sequences found in the carboxy-terminal heparin-binding domain of fibronectin. It promotes assembly of mesenchymal stem cell (MSC) spheroids into larger aggregates. Fibronectin Adhesion-promoting Peptide directly promotes the adhesion, spreading, and migration of endothelialcells by reacting with heparin binding domains of cells .
Macrophage-activating lipopeptide 2 TFA is an agonist of Toll like receptors TLR-2/TLR-6. Macrophage-activating lipopeptide-2 enhances endothelial nitric oxide synthase (eNOS) phosphorylation and endothelialcell release of NO, thereby improving vasodilation. Macrophage-activating lipopeptide-2 enhances endothelialadhesion of white blood cells and improve perfusion recovery and collateral growth in the hind limbs of hypercholesterolemic Apoe deficient mice undergoing experimental femoral artery ligation (FAL) .
pVEC (Cadherin-5) is a cell-penetrating 18-amino acid-long peptide derived from the murine sequence of the celladhesion molecule vascular endothelial cadherin. pVEC (Cadherin-5) is efficiently and rapidly taken up into cells, it can be used as a carrier peptide .
CXCL8 (54-72) is a C-terminal peptide based on the chemokine CXCL8. CXCL8 (54-72) has an interaction between a long and highly positively charged C-terminal region and a negative charge on the GAG that binds to the GAG. CXCL8 (54-72) can inhibit the adhesion and migration of neutrophils and adhesion of endothelialcells. CXCL8 (54-72) can be used to study chemokines in inflammatory response .
Vasculotide TFA is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide TFA binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelialcell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability . Vasculotide TFA alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide TFA with antibiotics reduces lung injury .
T7 Peptide is a protein synthesis inhibitor and anti-angiogenic agent, with a Kd of 10 nM for human transferrin receptor. T7 Peptide inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of 4E-BP1 in endothelialcells. T7 Peptide induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma .
T7 Peptide TFA is a protein synthesis inhibitor and anti-angiogenic agent, with a Kd of 10 nM for human transferrin receptor. T7 Peptide TFA inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of 4E-BP1 in endothelialcells. T7 Peptide TFA induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide TFA is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma .
Macrophage-activating lipopeptide 2 (MALP-2) is an agonist of Toll like receptors TLR-2/TLR-6. Macrophage-activating lipopeptide-2 can enhance endothelial nitric oxide synthase (eNOS) phosphorylation and endothelialcell release of NO, thereby improving vasodilation. Macrophage-activating lipopeptide-2 can enhance endothelialadhesion of white blood cells and improve perfusion recovery and collateral growth in the hind limbs of hypercholesterolemic Apoe deficient mice undergoing experimental femoral artery ligation (FAL) .
CD31 (PECAM-1) is platelet endothelialcelladhesion molecule-1, serves as the endothelialcell-specific receptor of clostridium perfringens b-Toxin (CPB). CD31 is also an ER-MP12 antigen, acts as a linker between mechanical stress, metabolism and inflammation. CD31 peptide is able to sustain phosphorylation of the CD31 ITIM686 and of SHP2 and to inhibit TCR-induced T-cell activation - .
F11R peptide TFA is a F11 receptor molecule. F11R peptide TFA inhibits anti-F11R antibody-induced platelet aggregation, and inhibits the adhesion of platelets to cytokine (TNFα and INF-γ)-inflammed endothelialcells. F11R peptide TFA can be used for research of atherosclerotic plaques and associated thrombotic disease .
Cadherin Peptide, avian is a calcium-dependent glycoprotein. Cadherin Peptide, avian takes part in homophilic cell-celladhesion and dose-dependently inhibits bovine brain microvessel endothelialcells (BBMECs) adhesion .
Fibronectin Adhesion-promoting Peptide (Heparin Binding Peptide) is one of the heparin-binding amino acid sequences found in the carboxy-terminal heparin-binding domain of fibronectin. It promotes assembly of mesenchymal stem cell (MSC) spheroids into larger aggregates. Fibronectin Adhesion-promoting Peptide directly promotes the adhesion, spreading, and migration of endothelialcells by reacting with heparin binding domains of cells .
CD31 (PECAM-1) TFA is platelet endothelialcelladhesion molecule-1, serves as the endothelialcell-specific receptor of clostridium perfringens b-Toxin (CPB). CD31 TFA is also an ER-MP12 antigen, acts as a linker between mechanical stress, metabolism and inflammation. CD31 TFA peptide is able to sustain phosphorylation of the CD31 ITIM686 and of SHP2 and to inhibit TCR-induced T-cell activation - .
REDV TFA is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV TFA can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV TFA can be used for the research of cell adhesion .
YIGSRC is a laminin-mimetic peptide. YIGSRC supports endothelialcelladhesion and tube formation. YIGSRC contains a cysteine residue for chemical modification to hydrogels via thiol-ene reaction. YIGSRC can be chemically modified onto hydrogels to improve in vitro vascularization .
SVVYGLR is an osteopontin-derived peptide. SVVYGLR can promote the differentiation of fibroblasts into myofibroblast-like cells and promote the production of type III collagen by cardiac fibroblasts. SVVYGLR can activate the adhesion, migration and tubule formation of endothelialcells in vitro. SVVYGLR promotes angiogenesis and wound healing and promotes the migration of dermal fibroblasts and keratinocytes. SVVYGLR can be used for research related to angiogenesis, dermal wounds and bone regeneration .
Peptide E5 is an antagonist targeting the CXCR4/CXCL12 axis. Peptide E5 blocks the CXCR4/CXCL12 axis, downregulates CXCR4 expression, and inhibits the phosphorylation of downstream Akt and Erk. Peptide E5 induces apoptosis, suppresses migration and adhesion of breast cancer cells. Peptide E5 inhibits CXCL12-mediated endothelial progenitor cell recruitment, thereby suppressing tumor angiogenesis. Peptide E5 is applicable to relevant research on breast cancer .
Intetumumab (CNTO 95) is a human monoclonal antibody targeting αv integrin, with a Kd value of 1-24 nM. Through high-affinity binding to αv integrin, Intetumumab inhibits its interaction with extracellular matrix proteins (such as vitronectin and fibronectin), thereby blocking the downstream focal adhesion kinase signaling pathway. This further inhibits the adhesion, migration and invasion of tumor cells as well as the proliferation of vascular endothelialcells, promotes cellapoptosis, and exerts anti-tumor and anti-angiogenic effects. Intetumumab can be used in research related to head and neck cancer, non-small cell lung cancer and uterine serous papillary carcinoma .
Etaracizumab (LM 609) is an αvβ3 integrin IgG mAb. Etaracizumab is developed to target αvβ3+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofαvβ3-mediated celladhesion, endothelialcell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
GSK1995057 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK1995057 selectively binds to TNFR1, blocks the binding of TNF-α and LT-α, and does not interfere with TNFR2 signaling. GSK1995057 inhibits the activation of NF-κB, JNK and MAPK pathways, alleviates apoptosis (apoptosis) and inflammatory responses (inhibiting IL-1β, IL-6, IL-10, TNF-α), and prevents viability loss of human nucleus pulposus cells. GSK1995057 inhibits the expression of cytokines and neutrophil adhesion molecules in human pulmonary microvascular endothelialcell monolayers, and reduces inflammatory responses and lung injury symptoms in non-human primates. GSK1995057 forms complexes with HAVH autoantibodies, thereby activating TNFR1 and triggering the release of cytokines and IL-8 in human cells. GSK1995057 can be used in research related to intervertebral disc degeneration and acute lung injury .
Anti-Mouse CD31/PECAM-1 Antibody (390) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse CD31/PECAM-1. Anti-Mouse CD31/PECAM-1 Antibody (390) reacts with mouse CD31, also known as PECAM-1 (platelet endothelialcelladhesion molecule). Anti-Mouse CD31/PECAM-1 Antibody (390) inhibits angiogenesis. Anti-Mouse CD31/PECAM-1 Antibody (390) can be used for the research of cancer, such as A549 tumor .
Anti-Mouse ICOSL/CD275 Antibody (HK5.3) is an anti-mouse ICOSL/CD275 IgG2a monoclonal antibody. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can inhibit the adhesion between T cells and endothelialcells. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can reduce the expansion of tissue resident (TR) Treg cells. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can be used for researches on inflammation and infection conditions such as influenza virus infection and arthritis .
Anti-E-Selectin Antibody (CL2) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human E-Selectin. Anti-E-Selectin Antibody (CL2) reacts with human E-selectin also known as CD62E, endothelial-leukocyte adhesion molecule 1 (ELAM-1), and leukocyte-endothelialcelladhesion molecule 2 (LECAM2). Anti-E-Selectin Antibody (CL2) directly blocks the binding of E selectin to carbohydrate ligands. Anti-E-Selectin Antibody (CL2) can be used for the detection of flow cytometry .
AT1412 is a CD9-binding antibody. AT1412 binds to the tetraspanin protein CD9 and modulates CD9 function by enhancing T celladhesion to endothelialcells (HUVECs) and transendothelial migration. AT1412 binds to B-ALL cell lines but not to T-ALL. AT1412 induces antibody-dependent cellular cytotoxicity in B-ALL cell lines. AT1412 binds to melanoma cells, B-ALL, gastric cancer, colorectal cancer, and pancreatic cancer cells [1] .
Gypenoside XLIX is a multifunctional bioactive compound that can be isolated from Gynostemma pentaphyllum, with a Ka value of 1.58 μM for its binding to SIRT1. Gypenoside XLIX acts as a PPAR-α agonist. It inhibits the activation of TLR4-mediated NF-κB signaling pathway by activating the Sirt1/Nrf2 signaling pathway, reduces ROS accumulation, and alleviates hepatic inflammatory injury in mice with sepsis-induced liver disease. Gypenoside XLIX targets SIRT1 to block YAP-NLRP3 activation and improve sepsis-induced cardiomyopathy. Gypenoside XLIX inhibits apoptosis (Apoptosis), pyroptosis (Pyroptosis), autophagy (Autophagy), lipid peroxidation, pro-inflammatory cytokines and anti-inflammatory cytokines. Gypenoside XLIX alleviates sepsis-induced splenic injury by inhibiting inflammation and oxidative stress, and mitigates sepsis-associated encephalopathy by targeting PPAR-α. Gypenoside XLIX prevents acute kidney injury by inhibiting IGFBP7/IGF1R-mediated programmed cell death and inflammation. Gypenoside XLIX inhibits the expression and activity of vascular celladhesion molecule-1 in cytokine-induced human endothelialcells. Gypenoside XLIX is applicable to research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis and chronic inflammation .
Rhamnocitrin is an anti-inflammatory and antioxidant agent that targets STIM-1, NFATc3 and MAPK pathways and can scavenge DPPH (IC50=28.38 mM). Rhamnocitrin selectively inhibits oxidative stress and inflammatory responses in vascular endothelialcells and neurons. Rhamnocitrin up-regulates miR-185 to inhibit STIM-1-mediated store-operated calcium entry (SOCE), thereby blocking NFATc3 nuclear translocation and downstream inflammatory factor expression, while inducing heme oxygenase HO-1 expression and regulating the ERK/p38 MAPK pathway, inhibiting antioxidant and pro-inflammatory cytokines (such as IL-6, IL-8) and adhesion molecules (such as ICAM-1, VCAM-1). Rhamnocitrin can be used in the study of endothelial-related inflammatory diseases (such as sepsis, acute lung injury, atherosclerosis) and neuroprotection (such as oxidative damage of PC12 cells) .
β-Estradiol 17-acetate (1,3,5(10)-Estratriene-3,17β-diol 17-acetate) is a long-acting endogenous estrogen precursor and also a cell viability and proliferation enhancer. β-Estradiol 17-acetate promotes the adhesion and proliferation of freshly isolated and revived female-derived human brain microvascular endothelialcells, and reverses the decreased viability of revived male-derived human brain microvascular endothelialcells. β-Estradiol 17-acetate exerts the microvascular protective effect of estrogen, enabling non-tumor human brain microvascular endothelialcells to be cultured in vitro for 2 months after cryopreservation. β-Estradiol 17-acetate is biotransformed into β-estradiol via hydrolase action in the in vitro skin of humans, hairless dogs, rats and hairless mice .
Aureothricin is a dithiolopyrrolone (DTP) antibiotic first isolated from Streptomyces and exhibits relatively broad-spectrum antibiotic activity. Aureothricin can inhibit adhesion of human umbilical vein endothelialcells (HUVECs) to vitronectin .
Gypenoside XLIX (Standard) is the analytical standard of Gypenoside XLIX. This product is intended for research and analytical applications. Gypenoside XLIX, a dammarane-type glycoside, is a prominent component of G. pentaphyllum. Gypenoside XLIX is a selective peroxisome proliferator-activated receptor (PPAR)-alpha activator and inhibits cytokine-induced vascular celladhesion molecule-1 (VCAM-1) overexpression and hyperactivity in human endothelialcells .
Rhamnocitrin (Standard) is the analytical standard of Rhamnocitrin. This product is intended for research and analytical applications. Rhamnocitrin is an anti-inflammatory and antioxidant agent that targets STIM-1, NFATc3 and MAPK pathways and can scavenge DPPH (IC50=28.38 mM). Rhamnocitrin selectively inhibits oxidative stress and inflammatory responses in vascular endothelialcells and neurons. Rhamnocitrin up-regulates miR-185 to inhibit STIM-1-mediated store-operated calcium entry (SOCE), thereby blocking NFATc3 nuclear translocation and downstream inflammatory factor expression, while inducing heme oxygenase HO-1 expression and regulating the ERK/p38 MAPK pathway, inhibiting antioxidant and pro-inflammatory cytokines (such as IL-6, IL-8) and adhesion molecules (such as ICAM-1, VCAM-1). Rhamnocitrin can be used in the study of endothelial-related inflammatory diseases (such as sepsis, acute lung injury, atherosclerosis) and neuroprotection (such as oxidative damage of PC12 cells) .
ESAM, short for Endothelial Cell Selective Adhesion Molecule, has the ability to induce aggregation, possibly through homophilic molecular interactions. It plays a role in molecular communication by binding to MAGI1, possibly forming complexes that contribute to intercellular signaling and adhesion processes. ESAM Protein, Human (HEK293, His) is the recombinant human-derived ESAM protein, expressed by HEK293 , with C-6*His labeled tag.
ESAM protein promotes aggregation through a homophilic molecular interaction and interacts with MAGI1, enhancing its role in cellular processes. ESAM Protein, Rat (HEK293, Fc) is the recombinant rat-derived ESAM protein, expressed by HEK293 , with C-hFc labeled tag.
ESAM protein promotes aggregation through a possible homophilic molecular interaction and interacts with MAGI1. ESAM Protein, Mouse (HEK293, His) is the recombinant mouse-derived ESAM protein, expressed by HEK293 , with C-His labeled tag.
The CD31/PECAM-1 protein is a cell adhesion molecule critical for leukocyte transendothelial migration (TEM) under inflammatory conditions.CD31/PECAM-1 also regulates bradykinin receptor BDKRB2 activation and modulates ERK1/2 activation in endothelial cells.CD31/PECAM-1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived CD31/PECAM-1 protein, expressed by HEK293 , with C-6*His labeled tag.
CD31/PECAM-1 Protein, a pivotal cell adhesion molecule, is essential for leukocyte transendothelial migration (TEM) in most inflammatory conditions. PECAM1 modulates bradykinin receptor BDKRB2 activation and regulates bradykinin- and hyperosmotic shock-induced ERK1/2 activation in endothelial cells. Signaling through PECAM-1 leads to the activation of neutrophils, monocytes and leukocytes. CD31/PECAM-1 Protein, Human (HEK293) is the recombinant human-derived CD31/PECAM-1 protein, expressed by HEK293 , with tag free.
CD31/PECAM-1 is a cell-cell adhesion protein. CD31/PECAM-1 regulates the activation of the slow hormone receptor BDKRB2 in endothelial cells and the activation of ERK1/2 induced by hypertonic shock and induces susceptibility to atherosclerosis. CD31/PECAM-1 mediates adhesion to endothelial cells and regulates tumor growth by forming new endothelial cell tubes. CD31/PECAM-1 Protein, Human (HEK293, Fc) is the recombinant human-derived CD31/PECAM-1 protein, expressed by HEK293 , with C-hFc labeled tag.
CD31/PECAM-1 Protein is a cell-cell adhesion protein that is found on the surface of platelets, monocytes, neutrophils, and some types of T-cells, and makes up a large portion of endothelial cell intercellular junctions. CD31/PECAM-1 Protein, Human (HEK293, His) is the recombinant human-derived CD31/PECAM-1 protein, expressed by HEK293 , with C-6*His labeled tag.
P-selectin is a Ca(2+)-dependent receptor on myeloid cells that critically binds to sialic acid-Lewis X on neutrophils and monocytes, promoting the interaction between activated endothelial cells or platelets and leukocytes interaction. This binding primarily to SELPLG/PSGL1 and PODXL2 is critical for rapid rolling of leukocytes during early inflammation. P-selectin Protein, Human (HEK293, His) is the recombinant human-derived P-selectin protein, expressed by HEK293 , with C-His labeled tag.
12(S)-HETE-d8 contains eight deuterium atoms at the 5, 6, 8, 9, 11, 12, 14 and 15 positions. 12(S)-HETE-d8 is intended for use as an internal standard for the quantification of 12(S)-HETE by GC- or LC-mass spectrometry (MS). 12(S)-HETE-d8 is the predominant lipoxygenase product of mammalian platelets. It enhances tumor celladhesion to endothelialcells, fibronectin, and the subendothelial matrix at 0.1 µM.
17-Epiestriol-d5-1 is the deuterium labeled 17-Epiestriol (HY-163712). 17-Epiestriol is an estrogen metabolite and a selective estrogen receptor (ER) β agonist. 17-epiestriol inhibits the mRNA and protein expression of the vascular celladhesion molecule VCAM-1 induced by tumor necrosis factor α (TNFα). 17-epiestriol also inhibits TNFα-induced VCAM-1 expression and prevents NF-κB migration to the nucleus. 17-Epiestriol also induces the mRNA and protein expression of endothelial nitric oxide synthase .
DSPE-PEG2000-YIGSR is a PEG compound which composed of DSPE and a biomimetic peptide YIGSR. YIGSR interacts with the 67 kDa laminin binding protein (LBP) and promotes adhesion and spreading of a large number of cell types including endothelialcells, fibroblasts and smooth muscle cells. DSPE-PEG2000-YIGSR can be used for drug delivery .
Human PECAM1 mRNA encodes the human platelet and endothelialcelladhesion molecule 1 (PECAM1) protein, a member of the immunoglobulin superfamily. PECAM1 is likely involved in leukocyte migration, angiogenesis, and integrin activation.
DSPE-PEG1000-YIGSR is a PEG compound which composed of DSPE and a biomimetic peptide YIGSR. YIGSR interacts with the 67 kDa laminin binding protein (LBP) and promotes adhesion and spreading of a large number of cell types including endothelialcells, fibroblasts and smooth muscle cells. DSPE-PEG1000-YIGSR can be used for drug delivery .
DSPE-PEG3400-YIGSR is a PEG compound which composed of DSPE and a biomimetic peptide YIGSR. YIGSR interacts with the 67 kDa laminin binding protein (LBP) and promotes adhesion and spreading of a large number of cell types including endothelialcells, fibroblasts and smooth muscle cells. DSPE-PEG3400-YIGSR can be used for drug delivery .
DSPE-PEG5000-YIGSR is a PEG compound which composed of DSPE and a biomimetic peptide YIGSR. YIGSR interacts with the 67 kDa laminin binding protein (LBP) and promotes adhesion and spreading of a large number of cell types including endothelialcells, fibroblasts and smooth muscle cells. DSPE-PEG5000-YIGSR can be used for drug delivery .
Inquiry Online
Your information is safe with us. * Required Fields.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
MedchemExpress Validation 03
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
MedchemExpress Validation 04
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website.
Privacy and Cookie Policy
